Corcept Therapeutics (CORT) CAO sells 1,540 shares at $114.16

Rhea-AI Filing Summary

Corcept Therapeutics chief accounting & technology officer Joseph Douglas Lyon reported a sale of 1,540 shares of common stock on August 3, 2026, at $114.16 per share in an open-market or private transaction. After this trade, he holds 5,495 shares, including 200, 178, 398 and 537 shares underlying unvested restricted stock awards granted on September 2, 2025, December 1, 2025, March 2, 2026 and June 1, 2026, which will fully vest on the one-year anniversaries of their grant dates if required conditions are satisfied.

Insider Trade Summary

Net Seller: 1,540 shares

Net Sell 1 txn

Insider Lyon Joseph Douglas

Role See Remarks

Sold 1,540 shs ($176K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,540	$114.16	$176K

Holdings After Transaction: Common Stock — 5,495 shares (Direct)

Footnotes (1)

1. F1. Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Key Figures

Shares sold: 1,540 shares Sale price: $114.16 per share Shares held after sale: 5,495 shares +4 more

7 metrics

Shares sold 1,540 shares Common stock sale reported for August 3, 2026

Sale price $114.16 per share Price received for the 1,540 common shares sold

Shares held after sale 5,495 shares Direct common stock holdings following the transaction

Unvested restricted shares (Sept. 2, 2025 grant) 200 shares Shares underlying unvested restricted stock award vesting one year after the September 2, 2025 grant date

Unvested restricted shares (Dec. 1, 2025 grant) 178 shares Shares underlying unvested restricted stock award vesting one year after the December 1, 2025 grant date

Unvested restricted shares (Mar. 2, 2026 grant) 398 shares Shares underlying unvested restricted stock award vesting one year after the March 2, 2026 grant date

Unvested restricted shares (Jun. 1, 2026 grant) 537 shares Shares underlying unvested restricted stock award vesting one year after the June 1, 2026 grant date

Key Terms

Common Stock, unvested restricted stock awards, grant date, vest

4 terms

Common Stock financial

"The security title for the reported transaction is Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

unvested restricted stock awards financial

"Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person"

grant date financial

"100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

vest financial

"100% of the shares underlying the restricted stock awards will vest on the one-year anniversary"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 05:49 PM Accepted by SEC EDGAR 08/05/2026 - 05:48 PM Learn about SEC filing dates

FAQ

What insider transaction did Corcept Therapeutics (CORT) report for Joseph Douglas Lyon?

Corcept Therapeutics reported that executive Joseph Douglas Lyon sold 1,540 shares of common stock at $114.16 per share on August 3, 2026, in an open-market or private transaction, as disclosed in his Form 4 filing.

How many Corcept Therapeutics (CORT) shares does Joseph Douglas Lyon hold after the sale?

Following the reported sale, Joseph Douglas Lyon holds 5,495 shares of Corcept Therapeutics common stock. This total includes unvested restricted stock awards that are scheduled to vest on the one-year anniversaries of their respective grant dates, subject to conditions.

At what price did Joseph Douglas Lyon sell Corcept Therapeutics (CORT) shares?

Joseph Douglas Lyon sold 1,540 shares of Corcept Therapeutics common stock at a price of $114.16 per share. The transaction is characterized as a sale in an open-market or private transaction under the Form 4 reporting codes.

What unvested restricted stock awards in CORT are included in Joseph Douglas Lyon’s holdings?

His reported holdings include 200, 178, 398 and 537 shares underlying unvested restricted stock awards granted on September 2, 2025, December 1, 2025, March 2, 2026 and June 1, 2026, which vest 100% one year after each grant date if conditions are met.

Was Joseph Douglas Lyon’s Corcept Therapeutics (CORT) sale under a Rule 10b5-1 trading plan?

The Form 4’s Rule 10b5-1 checkbox was not marked as affirmative, indicating the reported sale was not identified as being made under a Rule 10b5-1 trading plan in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lyon Joseph Douglas

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		S		1,540	D	$114.16	5,495(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Remarks:

Chief Accounting & Technology Officer

	/s/ Joseph Douglas Lyon	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)